Healthcare
Harrow Health, Inc.(HROW)
Live Price
Offline$42.93
+2.36% today
1Y Change
+33.78%
Window
Jun 26, 2025 โ Jun 17, 2026
- Market Cap
- $1.51B
- Revenue Growth
- +36.4%
- EPS Growth
- +71.4%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 26, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Harrow Health, Inc. (HROW) is a Healthcare stock with a market cap of $1.51B and listed on NASDAQ. The stock last traded around $42.93 and up 33.8% across the available one-year price window (Jun 26, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +36.4%, EPS growth of +71.4%, a dividend yield of 0.0%. What stands out right now is revenue +36.4%, EPS +71.4%, free cash flow +170.6% with operating margin 11.2% and ROIC 5.8%. Valuation sits in the middle of the pack at price/sales 5.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines HROW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+36.4% vs +7.6% peer median
Operating Margin
Below sector median
+11.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +36.4% and EPS at +71.4%, with operating margin around 11.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +1.1% | +6.8% | +22.0% |
2026 Mar 2, 2026 | -35.0% | -28.0% | -34.4% | -37.9% |
2025 Nov 10, 2025 | +50.0% | +13.5% | +18.0% | +41.7% |
Benchmark Edge
HROW vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HROW
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HROW Max Drawdown
-47.03%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HROW and SPY.
Company Overview
Harrow Health, Inc.
NASDAQ Global Market
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
- Leadership
- Mark L. Baum
- IPO Date
- Sep 28, 2007
- Employees
- 382
- Street Address
- 102 Woodmont Boulevard
- Mailing
- Nashville, TN, 37205
- Region
- Nashville, TN, US
- Reporting Currency
- USD
- Investor Line
- 615 733 4730
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 44.3
- Price/Sales
- 5.5
- Price/Book
- 28.4
Growth
- Revenue
- +36.4%
- EPS
- +71.4%
- Free Cash Flow
- +170.6%
Profitability
- Gross Margin
- 75.1%
- Operating Margin
- 11.2%
- Net Margin
- -1.9%
- ROE
- -10.0%
- ROIC
- 5.8%
Balance Sheet
- Debt/Equity
- 4.80
- Current Ratio
- 2.20
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.